Orbsen Therapeutics’ NEPHSTROM Clinical Trial Underway at Four European Union Locations Patients with diabetic kidney disease are being treated with a breakthrough stromal cell immunotherapy (October 2, 2018) Galway, Ireland — Orbsen Therapeutics, a biotechnology company focused on the discovery, development and commercialization of first-in-class stromal cell immunotherapies, announced that ORBCEL-M™, a second generation [...]